|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer显示文摘AIM: To evaluate the dosimetry, efficacy and toxicity of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy for patients with locally advanced cervical and upper thoracic esophageal cancer. METHODS: A retrospective study was performed on 7 patients who were definitively treated with IMRT and concurrent chemotherapy. Patients who did not receive IMRT radiation and concurrent chemotherapy were not included in this analysis. IMRT plans were evaluated to assess the tumor coverage and normal tissue avoidance. Treatment response was evaluated and toxicities were assessed. RESULTS: Five- to nine-beam IMRT were used to deliver a total dose of 59.4-66 Gy (median: 64.8 Gy) to the primary tumor with 6-MV photons. The minimum dose received by the planning tumor volume (PTV) of the gross tumor volume boost was 91.2%-98.2% of the prescription dose (standard deviation [SD]: 3.7%-5.7%). The minimum dose received by the PTV of the clinical tumor volume was 93.8%-104.8% (SD: 4.3%-11.1%) of the prescribed dose. With a median follow-up of 15 mo (range: 3-21 mo), all 6 evaluable patients achieved complete response. Of them, 2 developed localrecurrences and 2 had distant metastases, 3 survived with no evidence of disease. After treatment, 2 patients developed esophageal stricture requiring frequent dilation and 1 patient developed tracheal-esophageal fi stula. CONCLUSION: Concurrent IMRT and chemotherapy resulted in an excellent early response in patients with locally advanced cervical and upper thoracic esophageal cancer. However, local and distant recurrence and toxicity remain to be a problem. Innovative approaches are needed to improve the outcome. | Shu-Lian Wang Zhongxing Liao Helen Liu( Jaffer Ajani Stephen Swisher James D Cox Ritsuko Komaki | 2006 | World Journal of Gastroenterology2006，12，34： | 27 |
| 2 | Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection显示文摘 | Stephen R. Smalley Jacqueline K. Benedetti Daniel G. Haller Scott A. Hundahl Norman C. Estes Jaffer A. Ajani Leonard L. Gunderson Bryan Goldman James A. Martenson J. Milburn Jessup Grant N. Stemmermann Charles D. Blanke John S. Macdonald | 2012 | Journal of Clinical Oncology2012，，19： | 13 |
| 3 | Is endoscopic ultrasound examination necessary in the management of esophageal cancer?显示文摘Despite substantial efforts at early diagnosis, accurate staging and advanced treatments, esophageal cancer(EC) continues to be an ominous disease worldwide. Risk factors for esophageal carcinomas include obesity, gastroesophageal reflux disease, hard-alcohol use and tobacco smoking. Five-year survival rates have improved from 5% to 20% since the 1970 s, the result of advances in diagnostic staging and treatment. As the most sensitive test for locoregional staging of EC, endoscopic ultrasound(EUS) influences the development of an optimal oncologic treatment plan for a significant minority of patients with early cancers, which appropriately balances the risks and benefits of surgery, chemotherapy and radiation. EUS is costly, and may not be available at all centers. Thus, the yield of EUS needs to be thoughtfully considered for each patient. Localized intramucosal cancers occasionally require endoscopic resection(ER) for histologic staging or treatment; EUS evaluation may detect suspicious lymph nodes prior to exposing the patient to the risks of ER. Although positron emission tomography(PET) has been increasingly utilized in staging EC, it may be unnecessary for clinical staging of early, localized EC and carries the risk of false-positive metastasis(over staging). In EC patients with evidence of advanced disease, EUS or PET may be used to define the radiotherapy field. Multimodality staging with EUS, crosssectional imaging and histopathologic analysis of ER, remains the standard-of-care in the evaluation of early esophageal cancers. Herein, published data regarding use of EUS for intramucosal, local, regional and metastatic esophageal cancers are reviewed. An algorithm to illustrate the current use of EUS at The University of Texas MD Anderson Cancer Center is presented. | Tomas DaVee Jaffer A Ajani Jeffrey H Lee | 2017 | World Journal of Gastroenterology2017，23，5： | 11 |
| 4 | 转录因子Sp1在胃癌组织中的表达及其与胃癌预后的关系显示文摘目的探讨转录因子Sp1在胃癌组织中的表达情况及与胃癌患者预后的关系。方法采用免疫组化方法,检测Sp1在86例胃癌组织、53例淋巴结转移灶和57例正常胃黏膜组织中的表达情况,利用凝胶电泳迁移率分析(EMSA)检测正常胃黏膜组织和胃癌组织中的Sp1活性。应用Cox比例风险回归模型进行多因素分析,确立影响预后的独立因素。结果Sp1蛋白主要在黏液颈细胞胞核内表达,在胃小凹和腺上皮细胞中未见表达。同时,SP1在胃癌组织中高表达,而在胃癌邻近组织、胃癌间质细胞和腺体细胞中呈弱表达或无表达。在胃癌组织中,Sp1阴性表达、弱表达和高表达患者的中位生存时间分别为43个月、47个月和8个月,生存率差异有统计学意义(P<0.01)。多因素分析显示,Sp1表达、肿瘤分期是影响患者预后的独立因素。结论Sp1在胃癌组织中高表达,可作为预测胃癌患者预后的重要指标。 | 王理伟 李琦 华召来 周翡 Keping Xie Daoyan Wei James Yao Jaffer Ajani | 2007 | 中华肿瘤杂志2007，29，2： | 10 |
| 5 | Medical management of gastric cancer:A 2014 update显示文摘Gastric cancer represents a serious health problem on a global scale. It is the second leading cause of cancer-related death worldwide. Novel therapeutic targets are desperately needed because the meager improvement in the cure rate of about 10% realized by adjunctive treatments to surgery is unacceptable as > 50% patients with localized gastric cancer succumb to their disease. Either postoperative chemoradiotherapy(United States),pre-and post-operative chemotherapy(Europe),and adjuvant chemotherapy after a D2 resection(Asia) can all be regarded as standards of care in the localized gastric cancer management. In metastatic disease the addition of trastuzumab to chemotherapy is standard of care in Her2 positive disease. In the HER2 negative population,the treatments remain limited.In the first line setting,the standard of care is a combination of fluoropyrimidine and platinum containing chemotherapy,with or without epirubicin or docetaxel.The results of targeted therapy trials have by and large been disappointing,but none of these trials looked at an appropriately enriched population.Finally there is a meager overall survival benefit in treating patients with metastatic disease in the second line setting,with either irinotecan,docetaxel or ramucirumab however none of these drugs have been compared head to head in a well-powered randomized controlled trial. | Elena Elimova Hironori Shiozaki Roopma Wadhwa Kazuki Sudo Qiongrong Chen Jeannelyn S Estrella Mariela A Blum Brian Badgwell Prajnan Das Shumei Song Jaffer A Ajani | 2014 | World Journal of Gastroenterology2014，20，38： | 10 |
| 6 | Endoscopic management of esophageal cancer显示文摘Esophageal cancer(EC)generally consists of squamous cell carcinoma(which arise from squamous epithelium)and adenocarcinoma(which arise from columnar epithelium).Due to the increased recognition of risk factors associated with EC and the development of screening programs,there has been an increase in the diagnosis of early EC.Early EC is amenable to curative therapy by endoscopy,which can be performed by either endoscopic resection or endoscopic ablation.Endoscopic resection consists of either endoscopic mucosal resection(preferred in cases of adenocarcinoma)or endoscopic submucosal dissection(preferred in cases of squamous cell carcinoma).Endoscopic ablation can be performed by either radiofrequency ablation,cryotherapy,argon plasma coagulation or photodynamic therapy,amongst others.Endoscopy can also assist in the management of complications post-esophageal surgery,such as anastomotic leaks and perforations.Finally,there is a growing role for endoscopy to manage end-of-life palliative symptoms,especially dysphagia.The growing use of esophageal stents,debulking therapy and dilation can assist in improving a patient’s quality of life.In this review,we examine the multiple roles of endoscopy in the management of patients with EC. | Osman Ahmed Jaffer A Ajani Jeffrey H Lee | 2019 | World Journal of Gastrointestinal Oncology2019，11，10： | 6 |
| 7 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial显示文摘 | Hansjochen Wilke Kei Muro Eric Van Cutsem Sang-Cheul Oh Gy?rgy Bodoky Yasuhiro Shimada Shuichi Hironaka Naotoshi Sugimoto Oleg Lipatov Tae-You Kim David Cunningham Philippe Rougier Yoshito Komatsu Jaffer Ajani Michael Emig Roberto Carlesi David Ferry Kuma | 2014 | Lancet Oncology2014，，11： | 4 |
| 8 | Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis显示文摘 | Nirav Thosani Harvinder Singh Asha Kapadia Nobuo Ochi Jeffrey H. Lee Jaffer Ajani Stephen G. Swisher Wayne L. Hofstetter Sushovan Guha Manoop S. Bhutani | 2012 | Gastrointestinal Endoscopy2012，，2： | 3 |
| 9 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study显示文摘 | J.A. Ajani M. Buyse M. Lichinitser V. Gorbunova G. Bodoky J.Y. Douillard S. Cascinu V. Heinemann R. Zaucha A. Carrato D. Ferry V. Moiseyenko | 2013 | European Journal of Cancer2013，，： | 3 |
| 10 | Gastric cancer: Advances in adjuvant and adjunct therapy显示文摘 | Katsuhiko Higuchi MD Alexandria Phan MD Jaffer A. Ajani MD | 2003 | Current Treatment Options in Oncology2003，，5： | 2 |
| 11 | Docetaxel for gastric and esophageal carcinomas 显示文摘 | Ajani JA | 2002 | Oncology (Williston Park)2002，16，616： | 1 |
| 12 | Treatment of patients with upper gastrointestinal carcinomas 显示文摘 | Ajani JA | 1997 | Semin Oncot1997，24，619： | 1 |
| 13 | Chemotherapy for gastric carcinoma:new and old options显示文摘 | Ajani JA | 1998 | Oncology(Williston Park)1998，12，107： | 1 |
| 14 | Review of capecitabine as oral treatment of gastric,gastroesophageal,and esophageal cancer显示文摘 | Ajani J | 2006 | Cancer2006，107，2： | 1 |
| 15 | Clinical trials of vascular brachy-therapy for instent restenosis : update显示文摘 | Ajani A Kim HS Waksman B | 2001 | Cardiovasc Badiat Med2001，2，： | 1 |
| 16 | Docetaxel for gastric and esophageal carcinomas显示文摘 | Ajani JA | 2002 | Oncology (Williston Park)2002，6，66： | 1 |
| 17 | Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group显示文摘 | Ajani JA Moiseyemko VM Tjnlandin S | 2007 | J Clin Oncol2007，25，22： | 1 |
| 18 | Evolving chemotherapy for advanced gastric cancer显示文摘 | Ajani JA | 2005 | Oncologist2005，10，13： | 1 |
| 19 | Everolimus for previous- ly treated advanced gastric eaneer:resuhs of the randomized, double-blind,phase Ⅲ GRANITE-1 study 显示文摘 | Ohtsu A Ajani JA Bai YX | | J Clin On- col0，31，31： | 1 |
| 20 | Multieenter phase III comparison of cisplatin/S-I with eisplatin/infusional fluoroura- eil in advanced gastric or gastroesophageal adenocarcinoma study:the FLAGS trial显示文摘 | Ajani JA Rodriguez W Bodoky G | 2010 | J Clin Oncol2010，28，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员